secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2022-06-10T23:59:59+00:00
Accession:  0001193125-22-171489
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent announces positive initial Phase 2 APEX data for bezuclastinib in advanced systemic mastocytosis
--------------------------------------------------------------------------------

- All 11 patients achieved ≥50% serum tryptase reduction; median reduction 89%.
- All 8 evaluable patients had ≥50% bone marrow mast cell reduction; six cleared aggregates.
- No periorbital/peripheral edema, cognitive effects, or intracranial bleeding reported.
- Two prior avapritinib patients showed similar benefit; all remained on study at cutoff.
- Company to accelerate timelines; next APEX update by end of 2022; SUMMIT data in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312522171489/0001193125-22-171489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312522171489/d330856d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-171489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer